Identifying and validating novel targets with in vivo disease models: guidelines for study design

Area of Science:

• Pharmacology and Drug Discovery
• Translational Medicine
• Biomedical Research

Background:

• In vivo studies are crucial for identifying and validating novel drug targets.
• Current interpretation of in vivo data is often hindered by inadequate study design.
• Variability in protocols affects the reliability of target identification and validation.

Purpose of the Study:

• To highlight the importance of robust study design in in vivo target validation.
• To emphasize the need for species and target specificity in animal models.
• To advocate for standardized reporting criteria in preclinical studies.

Main Methods:

• Review of common study protocols in target identification and validation.
• Analysis of factors influencing data interpretation, including control groups and sample size.
• Examination of requirements for species and target specificity in animal models.

Main Results:

• Inadequate study design is a significant limitation in current in vivo research.
• Lack of clear rationale for species, strain, gender, and age selection impacts reproducibility.
• Discrepancies in study protocols complicate the validation of drug targets.

Conclusions:

• Standardized criteria, akin to those in human clinical trials, are necessary for in vivo target validation studies.
• Improved study design and reporting will enhance the reliability and reproducibility of preclinical drug discovery.
• Addressing these methodological issues is critical for advancing medicine through effective drug development.